Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) — Market Cap & Net Worth
Market Cap & Net Worth: Madrigal Pharmaceuticals Inc (MDGL)
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) has a market capitalization of $11.90 Billion ($11.90 Billion) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #1953 globally and #722 in its home market, demonstrating a 0.03% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Madrigal Pharmaceuticals Inc's stock price $518.74 by its total outstanding shares 22939969 (22.94 Million). Analyse Madrigal Pharmaceuticals Inc cash flow conversion to see how efficiently the company converts income to cash.
Madrigal Pharmaceuticals Inc Market Cap History: 2015 to 2026
Madrigal Pharmaceuticals Inc's market capitalization history from 2015 to 2026. Data shows growth from $282.62 Million to $11.78 Billion (20.86% CAGR).
Index Memberships
Madrigal Pharmaceuticals Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.49% | #37 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.03% | #224 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.71% | #25 of 263 |
Weight: Madrigal Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Madrigal Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Madrigal Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
13.94x
Madrigal Pharmaceuticals Inc's market cap is 13.94 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $2.11 Billion | $350.00K | -$31.15 Million | 6016.17x | N/A |
| 2018 | $2.59 Billion | $200.00K | -$32.81 Million | 12928.97x | N/A |
| 2020 | $2.55 Billion | $21.86K | -$197.44 Million | 116640.89x | N/A |
| 2021 | $1.94 Billion | $37.32K | -$241.08 Million | 52091.03x | N/A |
| 2024 | $7.08 Billion | $180.13 Million | -$465.89 Million | 39.30x | N/A |
| 2025 | $13.36 Billion | $958.40 Million | -$288.28 Million | 13.94x | N/A |
Competitor Companies of MDGL by Market Capitalization
Companies near Madrigal Pharmaceuticals Inc in the global market cap rankings as of May 2, 2026.
Key companies related to Madrigal Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Madrigal Pharmaceuticals Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Madrigal Pharmaceuticals Inc's market cap moved from $282.62 Million to $ 11.78 Billion, with a yearly change of 20.86%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $11.78 Billion | -11.78% |
| 2025 | $13.36 Billion | +88.72% |
| 2024 | $7.08 Billion | +33.36% |
| 2023 | $5.31 Billion | -20.28% |
| 2022 | $6.66 Billion | +242.52% |
| 2021 | $1.94 Billion | -23.77% |
| 2020 | $2.55 Billion | +22.02% |
| 2019 | $2.09 Billion | -19.17% |
| 2018 | $2.59 Billion | +22.80% |
| 2017 | $2.11 Billion | +516.04% |
| 2016 | $341.81 Million | +20.94% |
| 2015 | $282.62 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of Madrigal Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $11.90 Billion USD |
| MoneyControl | $11.90 Billion USD |
| MarketWatch | $11.90 Billion USD |
| marketcap.company | $11.90 Billion USD |
| Reuters | $11.90 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.